{"id":54739,"date":"2026-01-20T00:14:02","date_gmt":"2026-01-19T16:14:02","guid":{"rendered":"https:\/\/flcube.com\/?p=54739"},"modified":"2026-01-20T00:14:03","modified_gmt":"2026-01-19T16:14:03","slug":"novartiss-ianalumab-wins-fda-breakthrough-therapy-designation-for-sjogrens-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54739","title":{"rendered":"Novartis\u2019s Ianalumab Wins FDA Breakthrough Therapy Designation for Sj\u00f6gren\u2019s Disease"},"content":{"rendered":"\n<p><strong>Novartis AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE:\u202fNVS<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has granted <strong>Breakthrough Therapy Designation (BTD)<\/strong> to <strong>ianalumab<\/strong> for the treatment of <strong>Sj\u00f6gren\u2019s disease<\/strong>, the <strong>second most prevalent rheumatic autoimmune disease<\/strong>, for which there are <strong>no approved targeted therapies<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Novartis AG (NYSE:\u202fNVS)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Ianalumab (fully human monoclonal antibody)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Breakthrough Therapy Designation (BTD)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>U.S. FDA<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Sj\u00f6gren\u2019s disease<\/td><\/tr><tr><td><strong>Clinical Need<\/strong><\/td><td>No approved targeted treatments currently available<\/td><\/tr><tr><td><strong>Designation Date<\/strong><\/td><td>16\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Global Submission<\/strong><\/td><td>Planned starting early\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-disease-profile-sjogren-s-disease\">Disease Profile: Sj\u00f6gren\u2019s Disease<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Etiology:<\/strong> Serious, progressive <strong>autoimmune condition<\/strong> affecting multiple organs<\/li>\n\n\n\n<li><strong>Clinical Manifestations:<\/strong> Dryness, fatigue, pain, increased <strong>lymphoma risk<\/strong><\/li>\n\n\n\n<li><strong>Impact:<\/strong> Significant burden on quality of life; affects <strong>~0.5\u20111.0\u202f% of global population<\/strong><\/li>\n\n\n\n<li><strong>Market Gap:<\/strong> <strong>Second most prevalent rheumatic autoimmune disease<\/strong> after rheumatoid arthritis<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Dual action<\/strong> \u2013<\/li>\n<\/ul>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Depletes B\u2011cells<\/strong> via direct targeting<\/li>\n\n\n\n<li><strong>Inhibits B\u2011cell activation and survival<\/strong> via <strong>BAFF\u2011R (B\u2011cell activating factor receptor) blockade<\/strong><\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation:<\/strong> First\u2011in\u2011class <strong>BAFF\u2011R antagonist<\/strong> with <strong>B\u2011cell depletion capability<\/strong><\/li>\n\n\n\n<li><strong>Clinical Rationale:<\/strong> B\u2011cell dysregulation is a <strong>key driver<\/strong> of Sj\u00f6gren\u2019s pathogenesis<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-phase-3-neptunus-trials\">Clinical Evidence \u2013 Phase\u202f3 NEPTUNUS Trials<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Trial<\/th><th>Design<\/th><th>Key Findings<\/th><\/tr><\/thead><tbody><tr><td><strong>NEPTUNUS\u20111<\/strong><\/td><td>Phase\u202f3, randomized<\/td><td>Clinically meaningful benefit in disease activity<\/td><\/tr><tr><td><strong>NEPTUNUS\u20112<\/strong><\/td><td>Phase\u202f3, randomized<\/td><td>Reduction in patient burden, symptom improvement<\/td><\/tr><tr><td><strong>Combined Results<\/strong><\/td><td>\u2013<\/td><td>Consistent efficacy and safety across both studies<\/td><\/tr><tr><td>**Safety Profile<\/td><td>Well\u2011tolerated, manageable adverse events<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Efficacy:<\/strong> Ianalumab demonstrated <strong>improvement in disease activity<\/strong> and <strong>reduction in patient burden<\/strong> vs. placebo<\/li>\n\n\n\n<li><strong>Safety:<\/strong> Profile supportive of <strong>chronic dosing<\/strong> in autoimmune setting<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-competitive-landscape\">Market Impact &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Global Market<\/th><th>Addressable Population<\/th><\/tr><\/thead><tbody><tr><td><strong>Sj\u00f6gren\u2019s Disease Prevalence<\/strong><\/td><td>~40\u202fmillion<\/td><td>~20\u202fmillion diagnosed<\/td><\/tr><tr><td><strong>Targeted Therapy Penetration<\/strong><\/td><td>0\u202f%<\/td><td>0\u202f%<\/td><\/tr><tr><td><strong>Annual Cost (Targeted Therapy)<\/strong><\/td><td>\u2013<\/td><td>$35,000\u201145,000<\/td><\/tr><tr><td><strong>Peak Market Value (2035E)<\/strong><\/td><td>$12\u202fbillion<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Ianalumab Peak Share<\/strong><\/td><td>\u2013<\/td><td>25\u202f%<\/td><\/tr><tr><td><strong>Novartis Revenue (2032E)<\/strong><\/td><td>\u2013<\/td><td>$2.8\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rituximab<\/strong> (Roche) \u2013 Off\u2011label B\u2011cell depletion, limited efficacy<\/li>\n\n\n\n<li><strong>Belimumab<\/strong> (GSK) \u2013 BAFF inhibitor, approved for lupus, not Sj\u00f6gren\u2019s<\/li>\n\n\n\n<li><strong>Ianalumab<\/strong> \u2013 <strong>First BAFF\u2011R targeting agent<\/strong> with <strong>dual mechanism<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Submission:<\/strong> Novartis will submit <strong>regulatory applications<\/strong> starting <strong>early\u202f2026<\/strong>, leveraging <strong>BTD for accelerated FDA review<\/strong><\/li>\n\n\n\n<li><strong>Platform Value:<\/strong> Success in Sj\u00f6gren\u2019s validates <strong>BAFF\u2011R platform<\/strong> for potential expansion to <strong>other B\u2011cell mediated autoimmune diseases<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Leverages Novartis\u2019s <strong>global biologics network<\/strong>; commercial supply secured for launch<\/li>\n\n\n\n<li><strong>Commercial Readiness:<\/strong> Novartis\u2019s <strong>autoimmune sales force<\/strong> (1,200 US reps) can rapidly deploy upon approval<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory submissions, commercial forecasts, and market penetration for ianalumab. Actual results may differ due to FDA review outcomes, competitive dynamics, and market access challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis AG (NYSE:\u202fNVS) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[34,140,865],"class_list":["post-54739","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-breakthrough-therapy","tag-novartis","tag-nyse-nvs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novartis\u2019s Ianalumab Wins FDA Breakthrough Therapy Designation for Sj\u00f6gren\u2019s Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novartis AG (NYSE:\u202fNVS) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ianalumab for the treatment of Sj\u00f6gren\u2019s disease, the second most prevalent rheumatic autoimmune disease, for which there are no approved targeted therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54739\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis\u2019s Ianalumab Wins FDA Breakthrough Therapy Designation for Sj\u00f6gren\u2019s Disease\" \/>\n<meta property=\"og:description\" content=\"Novartis AG (NYSE:\u202fNVS) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ianalumab for the treatment of Sj\u00f6gren\u2019s disease, the second most prevalent rheumatic autoimmune disease, for which there are no approved targeted therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54739\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-19T16:14:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-19T16:14:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54739#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54739\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis\u2019s Ianalumab Wins FDA Breakthrough Therapy Designation for Sj\u00f6gren\u2019s Disease\",\"datePublished\":\"2026-01-19T16:14:02+00:00\",\"dateModified\":\"2026-01-19T16:14:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54739\"},\"wordCount\":439,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Breakthrough therapy\",\"Novartis\",\"NYSE: NVS\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54739#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54739\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54739\",\"name\":\"Novartis\u2019s Ianalumab Wins FDA Breakthrough Therapy Designation for Sj\u00f6gren\u2019s Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-19T16:14:02+00:00\",\"dateModified\":\"2026-01-19T16:14:03+00:00\",\"description\":\"Novartis AG (NYSE:\u202fNVS) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ianalumab for the treatment of Sj\u00f6gren\u2019s disease, the second most prevalent rheumatic autoimmune disease, for which there are no approved targeted therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54739#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54739\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54739#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis\u2019s Ianalumab Wins FDA Breakthrough Therapy Designation for Sj\u00f6gren\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis\u2019s Ianalumab Wins FDA Breakthrough Therapy Designation for Sj\u00f6gren\u2019s Disease - Insight, China&#039;s Pharmaceutical Industry","description":"Novartis AG (NYSE:\u202fNVS) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ianalumab for the treatment of Sj\u00f6gren\u2019s disease, the second most prevalent rheumatic autoimmune disease, for which there are no approved targeted therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54739","og_locale":"en_US","og_type":"article","og_title":"Novartis\u2019s Ianalumab Wins FDA Breakthrough Therapy Designation for Sj\u00f6gren\u2019s Disease","og_description":"Novartis AG (NYSE:\u202fNVS) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ianalumab for the treatment of Sj\u00f6gren\u2019s disease, the second most prevalent rheumatic autoimmune disease, for which there are no approved targeted therapies.","og_url":"https:\/\/flcube.com\/?p=54739","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-19T16:14:02+00:00","article_modified_time":"2026-01-19T16:14:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54739#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54739"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis\u2019s Ianalumab Wins FDA Breakthrough Therapy Designation for Sj\u00f6gren\u2019s Disease","datePublished":"2026-01-19T16:14:02+00:00","dateModified":"2026-01-19T16:14:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54739"},"wordCount":439,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Breakthrough therapy","Novartis","NYSE: NVS"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54739#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54739","url":"https:\/\/flcube.com\/?p=54739","name":"Novartis\u2019s Ianalumab Wins FDA Breakthrough Therapy Designation for Sj\u00f6gren\u2019s Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-19T16:14:02+00:00","dateModified":"2026-01-19T16:14:03+00:00","description":"Novartis AG (NYSE:\u202fNVS) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ianalumab for the treatment of Sj\u00f6gren\u2019s disease, the second most prevalent rheumatic autoimmune disease, for which there are no approved targeted therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54739#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54739"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54739#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis\u2019s Ianalumab Wins FDA Breakthrough Therapy Designation for Sj\u00f6gren\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54739"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54739\/revisions"}],"predecessor-version":[{"id":54746,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54739\/revisions\/54746"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}